Panagora Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Panagora Asset Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-42,134	Closed	-$1.06M	–	1166
2025 Q4	$1.06M	Buy	+42,134	New	+$989K	﹤0.01%	701
2025 Q2	–	Sell	-16,701	Closed	-$365K	–	1117
2025 Q1	$365K	Hold	16,701	–	–	﹤0.01%	892
2024 Q4	$533K	Sell	16,701 -12,685	-43%	-$381K	﹤0.01%	821
2024 Q3	$847K	Buy	29,386 +5,746	+24%	+$213K	﹤0.01%	772
2024 Q2	$907K	Buy	+23,640	New	+$1.07M	﹤0.01%	748
2023 Q2	–	Sell	-16,231	Closed	-$1.07M	–	1258
2023 Q1	$1.07M	Hold	16,231	–	–	0.01%	810
2022 Q4	$839K	Sell	16,231 -3,900	-19%	-$207K	0.01%	959
2022 Q3	$1.38M	Sell	20,131 -19	-0.1%	-$1.12K	0.01%	729
2022 Q2	$911K	Buy	+20,150	New	+$919K	0.01%	918

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Panagora Asset Management's APLS Position: Q1 2026 in Review

Panagora Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 42,134 shares — an estimated $1.06M sold.

Panagora Asset Management first reported a position in APLS in Q2 2022 and held it in 9 quarters. The position peaked at $1.38M in Q3 2022. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

Panagora Asset Management reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Panagora Asset Management sold 42,134 Apellis Pharmaceuticals shares in Q1 2026, an estimated $1.06M.
Panagora Asset Management first reported a position in Apellis Pharmaceuticals in Q2 2022 and held it in 9 quarters.
Panagora Asset Management's Apellis Pharmaceuticals position peaked at $1.38M in Q3 2022.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Panagora Asset Management's 13F filing for Q1 2026, filed 14 May 2026.